Complement Inhibitor and Enzyme/Protein Replacement Therapy

Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Texas Vendor Drug Program formulary coverage.

• Revision history
  • April 2022; March 2020; March 2018; March 2017; April 2015; March 2015; Feb. 2013. 
• Initially developed
  • Dec. 2012